Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740521 | 0.93 | FFAR1 (0.44) | FFAR1SMPD1RARBHRH3CASP3 | |
| SCHEMBL12740977 | 0.91 | FFAR1 (0.44) | FFAR1SMPD1RARBMAPTHRH3 | |
| SCHEMBL12741003 | 0.91 | FFAR1 (0.47) | FFAR1SMPD1RARBHRH3CASP3 | |
| SCHEMBL10302294 | 0.89 | FFAR1 (0.41) | FFAR1SMPD1RARBKDM4EMAPT | |
| SCHEMBL12741008 | 0.89 | FFAR1 (0.44) | FFAR1SMPD1RARBMAPTHRH3 | |
| SCHEMBL12736523 | 0.88 | SMPD1 (0.45) | FFAR1SMPD1RARBS1PR1 | |
| SCHEMBL12740969 | 0.87 | MAPT (0.45) | FFAR1KDM4EMAPTMAPK1PPARD | |
| SCHEMBL12822597 | 0.87 | FFAR1 (0.50) | FFAR1KDM4EMAPTMAPK1PPARD | |
| SCHEMBL10303112 | 0.87 | MAPT (0.47) | FFAR1KDM4EMAPTMAPK1PPARD | |
| SCHEMBL12736558 | 0.87 | RARB (0.47) | FFAR1SMPD1RARBMAPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR1 247/4885SMPD1 4718/4885RARB 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.